15175 Background: Metastatic PC has a dismal prognosis and few effective therapies, resulting in early death and poor quality of life. Weekly “metronomic dosing” of chemotherapy allows for increase dose density, dose intensity, and anti-angiogenic effects, yet affords good tolerability, allowing for a better quality of life and perhaps better efficacy. We report the encouraging interim results of the first nine patients treated twelve weeks with this POLF regimen. Methods: Nine patients ages 35 to 75 with metastatic biopsy proven PC were treated with weekly POLF (P: 60 mg/m2, O: 50mg/ m2, L: 20 mg/m2, F: 425 mg/m2) for twelve weeks. One patient (A.B.) also received intermittent Cetuximab. Glutathione, calcium, and magnesium were used to prevent Oxaliplatin- related neuropathy. Patients were seen weekly. Sequential CA 19–9 levels and CT scans were obtained. Results: After 12 weeks of treatments, 7/9 patients had greater than 50% reduction of CA 19–9 levels (see table ), improvement of cancer-related symptoms and shrinkage of tumor. Patient D.P. had a bilirubin of 27 and patient L.C. had bilirubin of 9.6, both of which normalized with treatment without need for stent placement. Patient A.B. was severely debilitated (ECOG 4) following progression of disease after 2 prior lines of chemotherapy but is alive and well after two years since diagnosis, with ECOG 0. The regimen was well tolerated with only one grade 3 neurotoxicity (L.C.) and one grade 3 diarrhea (B.P.). Median survival has not been reached. Conclusions: Weekly combination of Paclitaxel, Oxaliplatin, Leucovorin, and 5-FU has significant activity against advanced PC with manageable side effects. A Phase II study is opened to enrollment, and we welcome participation. [Table: see text] No significant financial relationships to disclose.
P1.04-57 Metronomic Dosing of Chemotherapy Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Non-Small Cell Lung Cancer